Holen Sie sich die Stockscreener-App
114.72
0.04%
-0.05
Handel nachbörslich:
114.72
Schlusskurs vom Vortag:
$114.77
Offen:
$114.75
24-Stunden-Volumen:
658.66K
Relative Volume:
0.31
Marktkapitalisierung:
$6.71B
Einnahmen:
$22.29M
Nettoeinkommen (Verlust:
$-228.93M
KGV:
-28.29
EPS:
-4.0547
Netto-Cashflow:
$-212.59M
1W Leistung:
-0.04%
1M Leistung:
+0.34%
6M Leistung:
+35.96%
1J Leistung:
+95.80%
1-Tages-Spanne:
$114.69
$114.90
1-Wochen-Bereich:
$114.65
$114.94
52-Wochen-Spanne:
$47.86
$114.94
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
114.72 | 6.71B | 22.29M | -228.93M | -212.59M | -4.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-22 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Key facts: Gilead Extends Arcellx Deal; $115+CVR; HIV Coverage Varies - TradingView
ACLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arcellx, Inc. (ACLX) stock price, news, quote and history - Yahoo Finance UK
Gilead Extends Tender Offer to Acquire Arcellx - BioSpace
Gilead extends Arcellx tender offer expiration date - MSN
ACLX Stock Price, Quote & Chart | ARCELLX INC (NASDAQ:ACLX) - ChartMill
Gilead Sciences Extends Tender Offer for Arcellx Shares to April 14, 2026 - geneonline.com
Gilead Extends Tender Offer To Acquire Arcellx - TradingView
Gilead Sciences, Arcellx see HSR waiting period expire March 31 - mlex.com
Arcellx (ACLX) 14D-9 amendment: Offer extended to Apr 24; HSR waiting period ended - stocktitan.net
Gilead (NASDAQ: ACLX) extends $115 per‑share tender, CVR pays $5 on condition - stocktitan.net
Arcellx (NASDAQ:ACLX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Arcellx Inc stock hits all-time high at 114.92 USD - Investing.com
ACLX PE Ratio & Valuation, Is ACLX Overvalued - Intellectia AI
Gilead extends Arcellx tender offer deadline to April 24 By Investing.com - Investing.com Canada
Piper Sandler Downgrades Arcellx(ACLX.US) to Hold Rating, Maintains Target Price $115 - Moomoo
Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Gilead to buy US biotech Arcellx for up to $7.8 billion - MSN
Aug PreEarnings: How does Arcellx Inc compare to its peersWeekly Loss Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
MACD Signal: What hedge funds are buying Arcellx Inc2026 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data - simplywall.st
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Hold" by Brokerages - marketbeat.com
Gilead’s Arcellx Deal Deepens Oncology Focus And Reshapes Investor Risk Profile - Sahm
Price-Driven Insight from (ACLX) for Rule-Based Strategy - Stock Traders Daily
ARCELLX PB Ratio: 16.50 — 103% Above Median - GuruFocus
Vanguard Realignment: Arcellx (ACLX) Beneficial Ownership Reported as 0% - Stock Titan
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition - Pharmaceutical Technology
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Benzinga
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Assessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price Momentum - Yahoo Finance
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Trade Report: Can Arcellx Inc maintain its current growth rateRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Arcellx (NASDAQ:ACLX) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Arcellx Inc stock hits all-time high at 114.82 USD By Investing.com - Investing.com Australia
Arcellx (NASDAQ:ACLX) Sets New 52-Week HighHere's What Happened - MarketBeat
Arcellx Inc stock hits all-time high at 114.82 USD - Investing.com
Arcellx (ACLX) CFO gifts 5,000 shares to family foundation - Stock Titan
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? - Finviz
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? (2026-03-19) - Seeking Alpha
Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset - MSN
JPMorgan Chase & Co. Decreases Holdings in Arcellx, Inc. $ACLX - MarketBeat
HC Wainwright & Co. downgrades Arcellx (ACLX) - MSN
M&A snapshot: Gilead acquires Arcellx for $7.8B - MSN
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - MSN
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
Gilead buys Arcellx to fast-track next-gen myeloma drug - MSN
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):